Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas (DOREMY)

Agents: Radiotherapy
Phase II
Status  Closed, active
Sponsor The Netherlands Cancer Institute

 

Further information: https://clinicaltrials.gov/ct2/show/NCT02106312

 

WHO is the trial for?
  • Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis)
  • Overall health status of the patient has to be good (ECOG performance status 0-2)
  • Patients must be able (physically, mentally and socially) to complete a series of radiotherapy (RT), followed by an observation period of 4-6 weeks and undergo surgery
  • Patients should not have received radiotherapy before

WHAT is the key question that this trial is attempting to answer?

The study tries to answer the question, if a reduced dose of preoperative radiotherapy (radiotherapy before surgery) in MLS from 50Gy to 36Gy is equally effective than the standard dose of 50Gy.

The efficacy will be assessed by the extent of the so called pathological response. It evaluates if and how much the tumour has shrunk during therapy.

WHY patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy strategy with potentially less side effects. It will further support the research in sarcomas and potentially help other patients with this disease. For more about the importance and benefits of joining clinical trials, please here.

WHEN will the trial be open?

 The study is closed for recruitment, but active.

WHERE is the trial available?

The trial is available in several study centers in the US, Denmark, The Netherlands, Norway and the UK. For further information please check here.

Study contacts:

Rick Haas, MD,Phd, Astrid Scholten, MD,PhD, tel. +31 20 5129111, email This email address is being protected from spambots. You need JavaScript enabled to view it.

STUDY DESIGN: What does the study look like?

All patients will undergo radiotherapy daily for five days a week. Every patient will receive radiotherapy 18 times (number of fractions) in total, with a daily dose (fraction size) of 2Gy. The overall treatment time will be 3.5-4 weeks and will amount to a total dosage of 36Gy (50Gy is currently standard treatment).

HOW do I get more information?

 Patient organisations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

SHARE your experience

 You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

 No results are available at this time. Future results will be linked here.


Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken